HC Wainwright & Co. maintains BioMarin Pharmaceutical at Neutral, keeps price target at $60

What happened

HC Wainwright & Co. kept its Neutral rating on BioMarin Pharmaceutical and maintained a $60 price target. That target implies 4.5% upside from the November 2 close of $57.44. Recent notes from other firms set targets between $60 and $122.

Confirmed

Global impact / market context

A Neutral rating means the analyst does not expect a big move up or down. Keeping the target at $60 signals the analyst sees limited upside after the stock closed at $57.44. That can shape how investors size their positions and whether they buy more shares.

Analyst inference

Other recent analyst targets range widely, from $60 to $122, so views on BioMarin differ. The spread suggests disagreement about future growth and risks. A clustered low end near the current share price points to cautious expectations among some analysts covering the company.

Analyst inference

What to watch

1. Watch whether HC Wainwright changes its Neutral rating or $60 target in future notes, since those updates would show a shift in the analyst's view. Confirmed
2. Watch for upcoming BioMarin announcements on drug trial results, sales, or spending plans, because those could prompt analysts to raise or cut price targets. Proposed
3. Watch whether other analysts move targets toward the $60 low end or keep them near the $122 high end, since narrowing would show agreement. Analyst inference

Evidence

• Original source link unavailable